Clinical trial
Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia
NCT02984995 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 8, 2016
- Completion date
- September 14, 2018
- Enrollment
- 37 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.